Tolerance induction by megadose hematopoietic progenitor cells: Expansion of veto cells by short-term culture of purified human CD34+ cells

Blood

Volumn 99, Issue 11, 2002, Pages 4174-4181

  Gur, Hilit ^a,b,c,d,e   Krauthgamer, Rita ^a,b,c,d,e   Berrebi, Alain ^a,b,c,d,e   Klein, Tirza ^a,b,c,d,e   Nagler, Arnon ^a,b,c,d,e   Tabilio, Antonio ^a,b,c,d,e   Martelli, Massimo F ^a,b,c,d,e   Reisner, Yair ^a,b,c,d,e  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; FLT3 LIGAND; STEM CELL FACTOR; THROMBOPOIETIN;

ARTICLE; CELL; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; PHENOTYPE; PRIORITY JOURNAL; STEM CELL MOBILIZATION; VETO CELL;

EID: 0036624744     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.11.4174     Document Type: Article

References (60)

1. Lapidot T, Lubin I, Terenzi A, Faktorowich Y, Erlich P, Reisner Y. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci U S A. 1990;87:4595-4599.
2. Tscherning T, Claesson MH. Veto-like down-regulation of T helper cell reactivity in vivo by injection of semi-allogeneic spleen cells. Immunol Lett. 1991;29:223-227.
3. + thymocytes. Blood. 1992;80:2406-2411.
4. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med. 1993;178:703-712.
5. + donor cells function as veto cells in the maintenance of tolerance across a major histocompatibility complex disparity in mixed-lymphoid radiation chimeras. Transplant Proc. 1993;25:331-333.
6. - cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity. 1999;11:579-590.
7. 1 T cells. Blood. 1999;94:3212-3221.
8. + T cells of Tc2 phenotype potently inhibit marrow graft rejection. Blood. 1998;91:4045-4050.
9. + stem cells: A new option for leukemia patients without an HLA-matched donor. Curr Opin Immunol. 2000;12:536-541.
10. Rachamim N, Gan J, Segall H, et al. Tolerance induction by "megadose" hematopoietic transplants: Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation. 1998;65:1386-1393.
11. Muraoka S, Miller RG. Cells in bone marrow and in T cell colonies grown from bone marrow can suppress generation of cytotoxic T lymphocytes directed against their self antigens. J Exp Med. 1980;152:54-71.
12. Claesson MH, Miller RG. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones, I: CTL clones express strong anti-self suppressive activity. J Exp Med. 1984;160:1702-1716.
13. Fink PJ, Rammensee HG, Benedetto JD, Staerz UD, Lefrancois L, Bevan MJ. Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes. J Immunol. 1984;133:1769-1774.
14. Fink PJ, Rammensee HG, Bevan MJ. Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them. J Immunol. 1984;133:1775-1781.
15. Fink PJ, Shimonkevitz RP, Bevan MJ. Veto cells. Annu Rev Immunol. 1988:6:115-137.
16. Sambhara SR, Miller RG. Programmed cell death of T cells signaled by the T cell receptor and the α3 domain of class I MHC. Science. 1991;252:1424-1427.
17. Thomas JM, Verbanac KM, Smith JP, et al. The facilitating effect of one-DR antigen sharing in renal allograft tolerance induced by donor bone marrow in rhesus monkeys. Transplantation. 1995;59:245-255.
18. Leshem B, Gotsman B, Kedar E. In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization. Cancer Immunol Immunother. 1984;17:117-123.
19. MacDonald HR, Cerottini JC, Ryser JE, et al. Quantitation and cloning of cytolytic T lymphocytes and their precursors. Immunol Rev. 1980;51:93-123.
20. Ott RL, Longnecker M, eds. An Introduction to Statistical Methods and Data Analysis. 5th Ed. Australia: Duxbury; 2001.
21. Muraoka S, Ehman DL, Miller RG. Irreversible inactivation of activated cytotoxic T lymphocyte precursor cells by "anti-self" suppressor cells present in murine bone marrow T cell colonies. Eur J Immunol. 1984;14:1010-1016.
22. Uberti J, Martilotti F, Chou TH, Kaplan J. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: Implications for use of LAK cells to prevent graftversus-host disease in allogeneic bone marrow transplantation. Blood. 1992;79:261-268.
23. Thomas JM, Carver FM, Kasten-Jolly J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation. 1994;57:101-115.
24. + CTLs as potent veto cells: Coexpression of CD8 and FasL is a prerequisite. Immunity. 2000;13:507-515.
25. + cells. Blood. 1993;82:3600-3609.
26. + cell expansion and expression of lineage markers during liquid culture of human progenitor cells. Stem Cells. 1995;13:167-174.
27. Katayama Y, Takenaka K, Mahmut N, et al. Replating potential of colony-forming units of granulocytes/macrophages (CFU-GM) expanded ex vivo by stem cell factor, interleukin (IL)-3, IL-6, granulocyte colony-stimulating factor, erythropoietin with or without thrombopoietin. Int J Hematol. 1998;68:157-168.
28. + peripheral blood progenitors. Leukemia. 1999;13:438-452.
29. + cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow. Bone Marrow Transplant. 1999;24:247-252.
30. + umbilical cord blood cells in a defined serum-free medium (QBSF-60) with early effect cytokines. J Hematother Stem Cell Res. 1999;8:609-618.
31. Lapidot T, Terenzi A, Singer TS, Salomon O, Reisner Y. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood. 1989;73:2025-2032.
32. Uharek L, Gassmann W, Glass B, Steinmann J, Loeffler H, Mueller-Ruchholtz W. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood. 1992;79:1612-1621.
33. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995;1:1268-1273.
34. Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84:2436-2446.
35. Hiruma K, Nakamura H, Henkart PA, Gress RE. Clonal deletion of postthymic T cells: Veto cells kill precursor cytotoxic T lymphocytes. J Exp Med. 1992;175:863-868.
36. Pierce GE, Watts LM. Do donor cells function as veto cells in the induction and maintenance of tolerance across an MHC disparity in mixed lymphoid radiation chimeras? Transplantation. 1993;55:882-887.
37. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today. 1995;16:437-440.
38. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948-3955.
39. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186-1193.
40. Butturini A, Seeger RC, Gale RP. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood. 1986;68:954-956.
41. Reisner Y, Ben-Bassat I, Douer D, Kaploon A, Schwartz E, Ramot B. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci U S A. 1986;83:4012-4015.
42. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987;43:842-847.
43. Brugger W, Kanz L. Ex vivo expansion of hematopoietic precursor cells. Curr Opin Hematol. 1996;3:235-240.
44. + progenitor cells by stem cell factor, interleukin-1β (IL-1β), IL-6, IL-3, interferon-γ, and erythropoietin. Blood. 1993;81:2579-2584.
45. Ohmizono Y, Sakabe H, Kimura T, et al. Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. Leukemia. 1997;11:524-530.
46. + cells: Amplification of progenitors from G-CSF and GM-CSF-mobilized peripheral blood. J Hematother. 1997;6:335-349.
47. Kobari L, Giarratana MC, Poloni A, et al. Flt 3 ligand, MGDF, Epo and G-CSF enhance ex vivo expansion of hematopoietic cell compartments in the presence of SCF, IL-3 and IL-6. Bone Marrow Transplant. 1998;21:759-767.
48. Kaplan DR, Hambor JE, Tykocinski ML. An immunoregulatory function for the CD8 molecule. Proc Natl Acad Sci U S A. 1989;86:8512-8515.
49. Claesson MH, Ropke C. Antiself suppressive (veto) activity of responder cells in mixed lymphocyte cultures. Curr Top Microbiol Immunol. 1986;126:213-223.
50. Cassell DJ, Forman J. Regulation of the cytotoxic T lymphocyte response against Qa-1 alloantigens. J Immunol. 1990;144:4075-4081.
51. + cells in the induction of peripheral tolerance. J Immunol. 1994;152:2222-2228.
52. Claesson MH. Veto cell H-2 antigens: Veto cell activity is restricted by determinants encoded by K, D, and I MHC regions. Cell Immunol. 1987;109:360-370.
53. + cells whose class I MHC can bind the peptide. J Immunol. 1994;152:1103-1109.
54. Qi Y, Berg R, Singleton MA, Debrick JE, Staerz UD. Hybrid antibody mediated veto of cytotoxic T lymphocyte responses. J Exp Med. 1996;183:1973-1980.
55. Asiedu C, Meng Y, Wang W, et al. Immunoregulatory role of CD8α in the veto effect. Transplantation. 1999;67:372-380.
56. George JF, Sweeney SD, Kirklin JK, Simpson EM, Goldstein DR, Thomas JM. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat Med. 1998;4:333-335.
57. + antiviral T cells by viral antigen-positive veto cells. J Virol. 1999;73:3826-3834.
58. Maris M, Sandmaier BM, Maloney DG, et al. Nonmyeloablative hematopoietic stem cell transplantation. Transfus Clin Biol. 2001;8:231-234.
59. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
60. Champlin R, Khouri I, Anderlini P, et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001;27(suppl 2):S13-S22.